Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth

Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via stimulation of endogenous phosphatases has received minimal attenti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Clin Invest
Egile Nagusiak: Sangodkar, Jaya, Perl, Abbey, Tohme, Rita, Kiselar, Janna, Kastrinsky, David B., Zaware, Nilesh, Izadmehr, Sudeh, Mazhar, Sahar, Wiredja, Danica D., O’Connor, Caitlin M., Hoon, Divya, Dhawan, Neil S., Schlatzer, Daniela, Yao, Shen, Leonard, Daniel, Borczuk, Alain C., Gokulrangan, Giridharan, Wang, Lifu, Svenson, Elena, Farrington, Caroline C., Yuan, Eric, Avelar, Rita A., Stachnik, Agnes, Smith, Blake, Gidwani, Vickram, Giannini, Heather M., McQuaid, Daniel, McClinch, Kimberly, Wang, Zhizhi, Levine, Alice C., Sears, Rosalie C., Chen, Edward Y., Duan, Qiaonan, Datt, Manish, Haider, Shozeb, Ma’ayan, Avi, DiFeo, Analisa, Sharma, Neelesh, Galsky, Matthew D., Brautigan, David L., Ioannou, Yiannis A., Xu, Wenqing, Chance, Mark R., Ohlmeyer, Michael, Narla, Goutham
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society for Clinical Investigation 2017
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5451217/
https://ncbi.nlm.nih.gov/pubmed/28504649
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89548
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak